Twenty-five antiretroviral agents have been marketed in the United States for the treatment of human immunodeficiency virus (HIV) infection/AIDS. The classification of these agents is reviewed and the properties of the five newest antiretroviral agents are discussed in detail. The specific indications for which the use of the new agents is recommended are identified, as are the risks and limitations of their use. The advantages and disadvantages of the new agents are considered in the context of comparisons with previously marketed antiretroviral agents. A rating (on a scale of 1 to 5) for each of the new drugs is provided based on an evaluation of their advantages and disadvantages
Comments